...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in chronic disease. >Ezetimibe: an update on its clinical usefulness in specific patient groups
【24h】

Ezetimibe: an update on its clinical usefulness in specific patient groups

机译：依泽替米贝（Ezetimibe）：其在特定患者群体中的临床实用性更新

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of pharmacological lipid modification is to reduce low-density lipoprotein cholesterol (LDL-C) as a means of either secondary or primary prevention of cardiovascular disease. Statins are the first-line therapy for pharmacological lipid modification. Ezetimibe is a drug which reduces LDL-C by selectively inhibiting intestinal cholesterol absorption. This provides an alternative pharmacological approach to that of statin therapy to reduce LDL-C. Ezetimibe has been shown to significantly reduce levels of LDL-C and recently, as demonstrated in the IMPROVE-IT trial, to reduce the rate of cardiovascular events in high-risk patients. Ezetimibe therefore has an important role in pharmacological lipid modification. In this paper, we examine the body of research behind ezetimibe and assess its current clinical applications in different patient subgroups.
机译：药理脂质修饰的目的是降低低密度脂蛋白胆固醇（LDL-C），作为心血管疾病的二级预防或一级预防。他汀类药物是药物脂质修饰的一线疗法。依泽替米贝是一种通过选择性抑制肠道胆固醇吸收来降低LDL-C的药物。这提供了他汀类药物疗法降低LDL-C的替代药理方法。依泽替米贝已被证明可以显着降低LDL-C的水平，最近，如IMPROVE-IT试验所证明的那样，依泽替米贝可以降低高危患者的心血管事件发生率。因此，依泽替米贝在药理脂质修饰中具有重要作用。在本文中，我们检查了依折麦布的研究内容，并评估了其在不同患者亚组中的当前临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号